Note 5 - Stock Incentive Plan

In April 2016, the Company’s Board of Directors and stockholders representing a majority of the Company’s outstanding stock at that time, approved the Monopar Therapeutics Inc. 2016 Stock Incentive Plan, as amended (the “Plan”), allowing the Company to grant up to an aggregate 700,000 shares of stock-based awards in the form of stock options, restricted stock units, stock appreciation rights and other stock-based awards to employees, non-employee directors and consultants. In October 2017, the Company’s Board of Directors voted to increase the stock award pool to 1,600,000 shares of common stock, which subsequently was approved by the Company’s stockholders. In April 2020, the Company’s Board of Directors voted to increase the stock award pool to 3,100,000 (an increase of 1,500,000 shares of common stock), which was approved by the Company’s stockholders in June 2020. In April 2021, the Company’s Board of Directors voted to approve an amendment to the 2016 Stock Incentive Plan to remove certain individual award limits and other provisions related to I.R.C. Section 162(m) and to update the limit on Incentive Stock Options to no more that 100% of the maximum aggregate number of shares which may be granted under the plan, which was approved by the Company’s stockholders in June 2021. In March 2022, the Company’s Board of Directors voted to increase the stock award pool to 5,100,000 (an increase of 2,000,000 shares of common stock), which was approved by the Company’s stockholders in June 2022.

There were no stock awards granted during the three months ended September 30, 2023.

Under the Plan, the per share exercise price for the shares to be issued upon exercise of an option shall be determined by the Plan Administrator, except that the per share exercise price shall be no less than 100% of the fair market value per share on the grant date. Fair market value is the Company’s closing price on the grant date on Nasdaq. Stock options generally expire after 10 years.

Stock option activity under the Plan was as follows: 

A summary of options outstanding as of September 30, 2023, is shown below:

Restricted stock unit activity under the Plan was as follows:

Stock option grants and fair values under the Plan were as follows:

As of  September 30, 2023, the aggregate intrinsic value of outstanding vested stock options was approximately $0.2 million (there were no unvested stock options that had intrinsic value) and the weighted-average exercise price in aggregate was $4.01 which includes $4.30 for fully vested stock options and $3.41 for stock options expected to vest. As of  September 30, 2023, unamortized unvested balance of stock-based compensation was $3.1 million, to be amortized over the following 2.6 years.

During the three months ended  September 30, 2023 and 2022, the Company recognized $256,670 and $ 204,360 of employee, non-employee director and consultant stock-based compensation expense as general and administrative expenses, respectively, and $217,468 and $186,382 as research and development expenses, respectively. During the nine months ended  September 30, 2023 and 2022, the Company recognized $757,303 and $613,525 of employee, non-employee director and consultant stock-based compensation expense as general and administrative expenses, respectively, and $666,340 and $634,321 as research and development expenses, respectively. The stock-based compensation expense is allocated on a departmental basis, based on the classification of the stock-based award holder. No income tax benefits have been recognized in the condensed consolidated statements of operations and comprehensive loss for stock-based compensation arrangements.